Maarten Cozijnsen

170 List of publications Included in this thesis Cozijnsen MA , Swagemakers S, Raatgeep HC, Simons-Oosterhuis Y, de Ridder L, Samsom JN. Infliximab has more impact than prednisolone on leukocyte RNA expression and serum inflammatory protein concentrations in peripheral blood of therapy naïve pediatric Crohn's disease patients. Preparing for publication Cozijnsen MA , Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, Russell RK, Ruemmele FM, Escher JC, de Ridder L, Koletzko S, Martín-de-Carpi J, Hyams J, Walters T, Griffiths A, Turner D. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn’s Disease. Clin Gastroenterol Hepatol. 2020 Jan;18(1):133-140. Cozijnsen MA , Samsom JN, de Ridder L. Anti-Tumour Necrosis Factor Therapy for Pediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability. Pediatr Drugs. 2018 Feb;20(1):19-28 Cozijnsen MA , van Pieterson M, Samsom JN, Escher JC, de Ridder L. Top-down Infliximab Study in Kids with Crohn’s disease (TISKids): an international multicentre randomised controlled trial. BMJ Open Gastroenterol. 2016 Dec 22;3(1):e000123 Cozijnsen MA , Escher JC, Griffiths A, Turner D, de Ridder L.Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2015 Apr;21(4):951-61 Cozijnsen MA , Duif V, Kokke F, Kindermann A, van Rheenen P, de Meij T, et al. Schaart M, Damen G, Norbruis O, Pelleboer R, Van den Neucker A, van Wering H, Hummel T, Oudshoorn J, Escher J, de Ridder L; Dutch PIBD Working Group Kids with Crohn and Colitis. Adalimumab therapy in children with Crohn disease previously treated with infliximab.J Pediatr Gastroenterol Nutr. 2015 Feb;60(2):205-10